Elucid Raises $27M in Series B Funding
- Elucid, a Boston, MA-company developing non-invasive medical software to characterize cardiovascular disease, raised $27M in Series B funding
- The round was led by an undisclosed strategic investor, with participation from Biovision Ventures, and existing investors
- The company intends to use the funds to accelerate growth and its development efforts
- The company is a medical technology company using interpretable and validated AI to provide physicians with a software platform to optimize treatment decisions for patients with cardiovascular disease
- This approach enables physicians to diagnose the direct cause of chest pain but also to determine if patients have early-stage heart disease which cannot be seen by alternative methods
- The software is available for commercial use in the U.S., Europe, and South Korea
